Calidi Net Working Capital from 2010 to 2025
| CLDI Stock | 1.52 0.08 5.56% |
Net Working Capital | First Reported 2010-12-31 | Previous Quarter 731 K | Current Value 767.5 K | Quarterly Volatility 10 M |
Check Calidi Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calidi Biotherapeutics' main balance sheet or income statement drivers, such as Tax Provision of 13.6 K, Depreciation And Amortization of 567.6 K or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.14 or PTB Ratio of 6.28. Calidi financial statements analysis is a perfect complement when working with Calidi Biotherapeutics Valuation or Volatility modules.
Calidi | Net Working Capital | Build AI portfolio with Calidi Stock |
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Check out the analysis of Calidi Biotherapeutics Correlation against competitors. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.